<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463643</url>
  </required_header>
  <id_info>
    <org_study_id>Z215-01</org_study_id>
    <nct_id>NCT02463643</nct_id>
  </id_info>
  <brief_title>To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Z-215 Compared With Rabeprazole Sodium in the Treatment of Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40
      mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A
      to D as defined by the LA classification grading system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Healing Rate Over 8 Weeks of Erosive Esophagitis</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Healing Rate Over 4 Weeks of Erosive Esophagitis</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">503</enrollment>
  <condition>Esophagitis, Reflux</condition>
  <arm_group>
    <arm_group_label>Z-215 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z-215 20 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z-215 40 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole Sodium 10 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-215 10mg</intervention_name>
    <description>Z-215 10mg, capsules</description>
    <arm_group_label>Z-215 10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-215 20mg</intervention_name>
    <description>Z-215 20mg, capsules</description>
    <arm_group_label>Z-215 20 mg/day</arm_group_label>
    <arm_group_label>Z-215 40 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-215 Placebo</intervention_name>
    <description>Z-215 placebo-matching capsules</description>
    <arm_group_label>Z-215 10 mg/day</arm_group_label>
    <arm_group_label>Z-215 20 mg/day</arm_group_label>
    <arm_group_label>Rabeprazole Sodium 10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Sodium</intervention_name>
    <description>Rabeprazole Sodium 10mg tablets</description>
    <arm_group_label>Rabeprazole Sodium 10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Sodium Placebo</intervention_name>
    <description>Rabeprazole Sodium Placebo placebo-matching tablets</description>
    <arm_group_label>Z-215 10 mg/day</arm_group_label>
    <arm_group_label>Z-215 20 mg/day</arm_group_label>
    <arm_group_label>Z-215 40 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In observation period, the participant must have endoscopically confirmed erosive
             esophagitis of Grade A to D, as defined by the LA classification grading system, and
             the target number of participants who are clearly Grade C or D is 20% (96
             participants) or more of the total participants.

          -  Outpatient (including inpatient for examination)

        Exclusion Criteria:

          -  Participants with a previous or current history of eosinophilic
             esophagitis,scleroderma, esophageal stenosis, esophageal varices, Barrett's esophagus
             ( columnar epithelium metaplasia&gt;=3 cm ) or high-grade dysplasia.However, participants
             with Schatzki's ring ( &gt;=20mm ) are allowed to be included.

          -  Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer
             (mucosal defect with white coating&gt;=3mm) within 28 days prior to observation period .
             Participants with above disease at endoscopy during the observation period.

          -  Participants with Zollinger-Ellison syndrome.Participants with suspected gastric acid
             hypersecretion disorders attributable to hyperparathyroidism and others.

          -  Participants with a previous history of surgery of esophagus,stomach or duodenum
             (excluding removal of benign polyp by endoscopic polypectomy) .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

